Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Caleb Birchler

Vascular Surgery Fairfield, OH Doctor of Osteopathy

NPI 1366892994 CMS profile 2724530

3050 Mack Rd Ste 310, Fairfield, OH 45014

Open in the dashboard

General payments

$23,675

250 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Caleb Birchler of Fairfield, OH is reported in the CMS Open Payments database as having received $23,675 across 250 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,723 62
2024 General $4,266 77
2023 General $2,830 54
2022 General $4,918 27
2021 General $4,505 18
2020 General $182 7
2019 General $251 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Caleb Birchler
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Caleb Birchler were reported at $6,723. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Caleb Birchler Vascular Surgery median Middle half National median
2019 $251 $796 $226–$2,363 $163
2020 $182 $348 $118–$1,110 $114
2021 $4,505 $471 $158–$1,421 $132
2022 $4,918 $725 $222–$2,183 $149
2023 $2,830 $836 $257–$2,440 $160
2024 $4,266 $909 $252–$2,619 $164
2025 $6,723 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $9,126 51 payments
  2. AngioDynamics, Inc. $3,140 14 payments
  3. W. L. Gore & Associates, Inc. $2,707 28 payments
  4. Silk Road Medical, Inc. $1,660 4 payments
  5. Inari Medical, Inc. $966 32 payments
  6. Shockwave Medical, Inc $605 10 payments
  7. Bard Peripheral Vascular, Inc. $605 5 payments
  8. Boston Scientific Corporation $449 6 payments
  9. Penumbra, Inc. $423 6 payments
  10. Globus Medical, Inc. $328 2 payments
  11. Other $3,666 92 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $13,855 232 payments
  2. Grant $6,000 2 payments
  3. Travel and Lodging $3,095 10 payments
  4. Education $724 6 payments
Products named General payments · program years 2019–2025
  1. ENDURANT IIS $5,193 38 payments
  2. Endurant $3,407 5 payments
  3. ANGIOVAC $1,781 2 payments
  4. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $1,660 4 payments
  5. ENROUTE Transcarotid Stent $1,660 4 payments
  6. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,660 4 payments
  7. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,660 4 payments
  8. EXCLUDER Conformable AAA Endoprosthesis with Active Control $1,306 11 payments
  9. CT THROMBECTOMY SYSTEM KIT $1,177 34 payments
  10. FLOWTRIEVER CATHETER, S $1,177 34 payments
  11. Other $9,352 177 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 5 drugs

Part D claims

116

Median for Vascular Surgery: 122

Drug cost

$11,434

Median for Vascular Surgery: $14,135

Branded share of claims

75.9%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 13 $10,876
Clopidogrel Clopidogrel Bisulfate Brand 38 $323
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 37 $112
Oxycodone Hcl Generic 14 $72
Atorvastatin Calcium Generic 14 $51

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 102 billing codes

Paid by Medicare

$231,318

Medicare's payments for the services billed

Medicare patients

376

Average age 74

Services billed

1,251

171 women, 205 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 50%
Diabetes 46%
Chronic kidney disease 46%
Heart failure 38%
Depression 35%
Atrial fibrillation 34%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kcentra
  • CSL Behring $26
$26 — —
ZENPEP
  • AIMMUNE THERAPEUTICS, INC. $19
$19 — —
DALVANCE
  • AbbVie, Inc. $15
$15 — —
TEFLARO
  • AbbVie, Inc. $15
$15 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $13
$13 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

250 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record